Semaglutide

Most Common Uses

Semaglutide is primarily prescribed as a once-weekly subcutaneous injection to manage type 2 diabetes in adults. It is used alongside diet and exercise to improve blood sugar control when metformin or other oral medications alone are not enough. Patients with type 2 diabetes often start semaglutide to lower HbA1c levels, reduce fasting and post-meal glucose spikes, and support steady glycemic control throughout the day. The medication is available as an injectable formulation under the brand name Ozempic and as an oral tablet under the brand name Rybelsus.

In higher doses, semaglutide is approved under the brand name Wegovy for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition, such as hypertension, dyslipidemia, or obstructive sleep apnea. It is taken once weekly to reduce appetite, slow gastric emptying, and promote sustained weight loss when combined with a reduced-calorie diet and increased physical activity.

Semaglutide also appears in clinical practice to lower cardiovascular risk in people with type 2 diabetes who have established heart disease or are at high risk. Studies show it reduces the likelihood of major cardiovascular events, including heart attack, stroke, and cardiovascular death, making it a preferred option for many patients with both diabetes and heart concerns.

In some cases, physicians prescribe semaglutide off-label for weight management in non-diabetic people with obesity, though this use depends on local regulations and medical judgment. With its long half-life of about one week, semaglutide allows convenient weekly dosing that maintains steady effects on appetite, glucose regulation, and body weight over time. These applications make semaglutide one of the most widely used GLP-1 receptor agonists in diabetes care, obesity treatment, and cardiovascular risk reduction.

History & Development

Semaglutide was developed by Novo Nordisk, a pharmaceutical company with a long-standing focus on diabetes and metabolic disorders. Building on their experience with earlier GLP-1 receptor agonists, Novo Nordisk set out to create a molecule that would not only be more effective but also offer greater convenience for patients through less frequent dosing. The result was semaglutide, a modified version of human GLP-1 designed to resist degradation and maintain prolonged activity in the body.

Initial development began in the early 2010s, and by 2012, Novo Nordisk had launched clinical trials following encouraging preclinical results. These studies demonstrated that semaglutide could sustain GLP-1 activity for longer durations than existing treatments, prompting further investment into its clinical development for both diabetes and weight management.

In December 2017, the U.S. Food and Drug Administration (FDA) approved semaglutide under the brand name Ozempic for the treatment of type 2 diabetes. This once-weekly injectable formulation quickly gained attention for its strong efficacy in lowering blood glucose and promoting weight loss. Just two years later, in September 2019, an oral formulation named Rybelsus received FDA approval, making history as the first oral GLP-1 receptor agonist to reach the market.

Semaglutide’s impact expanded even further in June 2021 with the FDA approval of Wegovy, a higher-dose version indicated specifically for chronic weight management. Aimed at adults with obesity or those who are overweight with at least one weight-related condition, Wegovy marked a major milestone in obesity treatment, offering a new therapeutic option backed by robust clinical data.

Mechanism of Action

Semaglutide belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists and mimics the actions of the natural hormone GLP-1. It binds to and activates GLP-1 receptors on pancreatic beta cells in a glucose-dependent manner, which stimulates insulin secretion only when blood glucose levels are elevated. This helps prevent hypoglycemia while improving postprandial glucose control. At the same time, semaglutide suppresses glucagon release from pancreatic alpha cells during periods of high blood sugar, reducing hepatic glucose output.

The peptide slows gastric emptying, which delays nutrient absorption and produces a more gradual rise in blood glucose after meals. In the central nervous system, semaglutide activates GLP-1 receptors in hypothalamic regions that regulate appetite, increasing feelings of satiety and reducing hunger, which leads to lower calorie intake and sustained weight loss. Semaglutide also exerts direct effects on cardiovascular tissue, improving endothelial function, reducing inflammation, and lowering blood pressure in many patients.

Structural modifications give semaglutide a prolonged plasma half-life of approximately one week. An aminoisobutyric acid (Aib) substitution at position 8 protects against degradation by dipeptidyl peptidase-4 (DPP-4), while attachment of a C18 fatty diacid chain via a γ-glutamic acid spacer promotes strong binding to serum albumin. These changes enable once-weekly subcutaneous dosing and maintain steady receptor activation over time.

Through these combined actions, enhanced insulin secretion, reduced glucagon, delayed gastric emptying, appetite suppression, and favorable metabolic and cardiovascular effects, semaglutide provides durable glycemic control, substantial weight reduction, and cardiovascular risk reduction in patients with type 2 diabetes and obesity.

Structure and Pharmacology

Semaglutide is a man-made version of a natural hormone called GLP-1, which helps control blood sugar. Scientists made three main changes to the natural hormone to make it work better: one change prevents it from breaking down too quickly, another makes it more stable in the body, and a third adds a small fatty chain that helps it stay in the bloodstream longer. These modifications allow semaglutide to be effective for a full week with just one injection. Its molecular weight is about 4114 g/mol.

It works by helping the pancreas release insulin when blood sugar is high and reducing the hormone glucagon that raises blood sugar. It also slows down how fast the stomach empties food, which lowers the rise in blood sugar after meals and helps people feel full. In the brain, semaglutide reduces appetite, helping with long-term weight loss. Additionally, it can improve blood vessel health, reduce inflammation, and lower blood pressure, which can reduce the risk of heart problems.

Semaglutide stays active in the body for about a week, so weekly injections maintain steady effects without big ups and downs in blood sugar. The body breaks it down like a protein, with very little being removed by the kidneys. These properties make semaglutide effective for controlling blood sugar in type 2 diabetes, supporting significant weight loss, and lowering heart-related risks in high-risk patients.

Dosages

Semaglutide is administered as a once-weekly subcutaneous injection using prefilled pens. For type 2 diabetes treatment (Ozempic brand), therapy usually begins with 0.25 mg once weekly for the first four weeks to allow the body to adjust and reduce gastrointestinal side effects. The dose is then increased to 0.5 mg weekly. Depending on user’s response and glycemic control needs, the dose can be raised to 1 mg weekly after at least four weeks on 0.5 mg, and in some cases further to 2 mg weekly after at least four weeks on 1 mg. Injections can be given any day of the week at roughly the same time, with or without meals.

For chronic weight management in adults with obesity or overweight with weight-related comorbidities (Wegovy brand), treatment follows a gradual titration schedule to improve tolerability. The starting dose is 0.25 mg once weekly for four weeks, followed by 0.5 mg for four weeks, then 1 mg for four weeks, then 1.7 mg for four weeks, and finally 2.4 mg once weekly as the maintenance dose. If patients experience persistent gastrointestinal side effects during escalation, the dose can be temporarily reduced or the increase delayed by an additional four weeks.

Missed doses should be taken as soon as remembered within five days of the scheduled injection. If more than five days have passed, the missed dose is skipped and the next dose is taken on the regular day. No double dosing is used to make up for missed injections. The long plasma half-life of approximately one week allows consistent weekly administration without daily fluctuations. Careful dose escalation and monitoring help manage common side effects like nausea, vomiting, and diarrhea, particularly during the initial weeks. All doses are delivered subcutaneously in the abdomen, thigh, or upper arm, with rotation of injection sites recommended to minimize local reactions.

• Ozempic® (subcutaneous injection): Start at 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg; may escalate to 1 mg or 2 mg weekly based on response.
• Rybelsus® (oral): Begin with 3 mg once daily for 30 days, then increase to 7 mg; may go up to 14 mg daily if needed. Taken with no more than 4 ounces of water, 30 minutes before food or other medications.
• Wegovy® (subcutaneous injection): Initiated at 0.25 mg weekly, titrated monthly up to a maintenance dose of 2.4 mg weekly for weight loss.

Warnings and Cautions

Semaglutide requires careful attention due to its effects on the gastrointestinal system and metabolism. Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are common, especially during the first few weeks or when increasing the dose. These symptoms often lessen over time, but some people find them persistent enough to require dose adjustments or temporary pauses.

Pancreatitis has been reported in patients taking semaglutide, with symptoms including severe abdominal pain that may radiate to the back, accompanied by nausea and vomiting. Anyone experiencing these signs should stop the medication and seek immediate medical attention. Gallbladder problems, such as cholelithiasis or cholecystitis, occur more frequently with semaglutide, particularly during rapid weight loss, so patients with a history of gallbladder disease need monitoring.

Semaglutide carries a boxed warning for the risk of thyroid C-cell tumors, based on rodent studies showing dose-dependent increases in medullary thyroid carcinoma. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Hypoglycemia risk rises when semaglutide is combined with insulin, sulfonylureas, or other glucose-lowering agents, so dose reductions of those medications may be necessary, along with regular blood glucose checks.

Allergic reactions, though uncommon, can occur and may include rash, itching, swelling, or difficulty breathing. Injection-site reactions such as redness, itching, or pain are possible and usually mild. Semaglutide slows gastric emptying, which can affect oral medication absorption; patients taking oral contraceptives, antibiotics, or other time-sensitive drugs should discuss timing with their healthcare provider.

Because of its long half-life of about one week, semaglutide remains in the body for several weeks after the last dose, so effects (both therapeutic and side effects) can persist even after stopping. Women of childbearing potential should use effective contraception, as rapid weight loss or changes in glycemic control may affect fertility or pregnancy outcomes. Patients with severe gastrointestinal disease, gastroparesis, or a history of severe pancreatitis should avoid semaglutide.

Regular monitoring of kidney function is recommended in patients with renal impairment, as dehydration from gastrointestinal side effects can worsen kidney function. All users should adhere to a gradual dose increase schedule to improve tolerability and report any persistent or severe symptoms.

Clinical Trials

SUSTAIN Trials: Semaglutide in Type 2 Diabetes

The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) trial series formed the backbone of semaglutide’s approval for managing type 2 diabetes. These large-scale, randomized controlled studies assessed both safety and efficacy in a variety of patient populations and clinical contexts.

• SUSTAIN-6 was particularly significant, as it focused on cardiovascular outcomes in patients with type 2 diabetes at high cardiovascular risk. The trial demonstrated that semaglutide not only improved glycemic control but also reduced the risk of major adverse cardiovascular events (MACE), including nonfatal heart attacks and strokes. These findings helped establish semaglutide as a cardioprotective agent in addition to a glucose-lowering therapy.
• SUSTAIN-7 directly compared semaglutide to another GLP-1 receptor agonist, dulaglutide. Results showed that semaglutide led to greater reductions in both HbA1c levels and body weight, positioning it as a superior option in terms of glycemic control and weight-related benefits.

STEP Trials: Semaglutide in Obesity and Weight Management

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical program evaluated the impact of semaglutide 2.4 mg on weight loss in individuals with obesity or overweight, with or without type 2 diabetes. These trials redefined the role of GLP-1 receptor agonists in obesity management.

• STEP-1: In this pivotal trial, participants receiving 2.4 mg semaglutide alongside lifestyle counseling lost an average of 14.9% of their body weight over 68 weeks. The results far exceeded those seen with previous anti-obesity medications, setting a new benchmark in medical weight loss.
• STEP-3: This trial added an intensive lifestyle intervention to the semaglutide regimen. The combination led to even greater reductions in body weight, highlighting the additive benefits of behavioral support alongside pharmacological therapy.
• STEP-4: Designed to assess the importance of continued treatment, this trial randomized patients who had already achieved weight loss on semaglutide to either continue the medication or switch to placebo. Those who discontinued semaglutide regained much of the lost weight, underscoring the need for ongoing treatment to maintain results.

Ongoing and Emerging Areas of Research

Semaglutide’s potential applications continue to expand beyond type 2 diabetes and obesity. A number of ongoing clinical trials are exploring its utility in other serious conditions:

• Addiction Treatment: Early-stage trials are evaluating semaglutide’s effect on reducing cravings and consumption in alcohol use disorder, based on its role in appetite and reward signaling.

• NASH (Non-Alcoholic Steatohepatitis): Researchers are investigating semaglutide for its potential to reduce liver inflammation and fibrosis in patients with NASH, a condition closely tied to metabolic dysfunction.

• SELECT Trial: This major cardiovascular outcomes trial is studying semaglutide’s impact on heart health in people with obesity but without diabetes. Results could significantly influence preventive cardiology for non-diabetic patients.

• Neurodegenerative Diseases: Preliminary research is examining semaglutide’s neuroprotective properties, including potential benefits for conditions like Alzheimer’s disease, due to its effects on inflammation and metabolic pathways in the brain

Research Findings

Semaglutide for Weight Loss

Semaglutide is a long-acting GLP-1 receptor agonist that allows for once-weekly subcutaneous administration and has been approved by both the EMA and FDA for the treatment of type 2 diabetes. Clinical evidence shows that once-weekly semaglutide provides superior weight-loss effects compared to other GLP-1 receptor agonists in patients with type 2 diabetes. Because of its strong impact on body weight, semaglutide has attracted attention not only as an antidiabetic drug, but also as a potential treatment for obesity.

In a phase II dose-finding trial involving patients with obesity but without type 2 diabetes, once-daily subcutaneous semaglutide produced significantly greater weight loss than both placebo and liraglutide. The degree of weight reduction exceeded the minimum efficacy criteria required by both the FDA and EMA for anti-obesity medications. No major safety concerns were identified, supporting the conclusion that semaglutide is a promising future therapy for obesity. [1] 

Baseline Cardiovascular Profile

The SELECT study is a large cardiovascular outcomes trial designed to assess whether semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), can reduce cardiovascular events in people who are overweight or obese but do not have diabetes. The study specifically enrolled those with established cardiovascular disease, such as a prior heart attack, stroke, or peripheral artery disease. While this paper reports only the baseline characteristics of the participants, it provides important context for understanding how semaglutide may impact cardiovascular risk in this population.

GLP-1 receptor agonists, including semaglutide, are known to improve multiple cardiovascular risk factors, such as blood pressure, lipid profiles, inflammation, body weight, central adiposity, and glycemic control, even in non-diabetic or prediabetic people. Prior studies in people with type 2 diabetes have shown that these agents can reduce major adverse cardiovascular events (MACE), which include cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. SELECT is the first large trial designed to test whether these cardiovascular benefits extend to non-diabetic people with obesity.

The baseline data show that the study population has a high cardiovascular risk, with an average age of 62 years, BMI of 33 kg/m², 76% having a prior myocardial infarction, 23% a prior stroke, and 24% chronic heart failure. Two-thirds of participants were prediabetic, and most were already receiving cardiovascular medications such as statins, blood pressure-lowering drugs, and antiplatelet therapy. This high-risk population will allow the trial to evaluate whether semaglutide’s metabolic and weight-loss effects can translate into meaningful reductions in cardiovascular events across different subgroups. [2]

Improves Blood Sugar Control in Type 2 Diabetes

The 12-week trial demonstrated that once-weekly semaglutide significantly improved blood sugar control in people with type 2 diabetes. It enhanced beta cell function, increasing both first- and second-phase insulin secretion compared with placebo, which means the pancreas was better able to respond to blood glucose. At the same time, semaglutide reduced fasting and postprandial glucose levels and suppressed glucagon, a hormone that raises blood sugar, leading to overall better glycaemic control throughout the day.

Importantly, the study showed that semaglutide restored beta cell responsiveness to levels closer to healthy individuals, as measured by graded glucose infusion tests. This improved insulin-glucose dynamics, helping maintain blood sugar within target ranges. The drug’s effects were observed across multiple measures, including insulin secretion rate, C-peptide levels, and glucose response to meals.

Overall, semaglutide not only lowered blood sugar but also acted on the underlying pancreatic dysfunction in type 2 diabetes, combining enhanced insulin secretion and reduced glucagon response. These mechanisms make it a promising therapy for durable glycaemic control in people with type 2 diabetes, especially those who are overweight or obese. [3]

Semaglutide Protects Kidney Function in Type 2 Diabetes

One study concluded that semaglutide significantly protects kidney function in people with type 2 diabetes and chronic kidney disease (CKD). Over a median follow-up of 3.4 years, semaglutide reduced the risk of major kidney events, such as kidney failure, a ≥50% drop in eGFR, or kidney-related death, by 24% compared with placebo. The drug also slowed the decline in kidney function, as shown by a less steep eGFR slope.

Additionally, semaglutide lowered the risk of cardiovascular death and all-cause mortality, highlighting its dual benefit for kidney and heart health in this high-risk population. Overall, the trial demonstrates that semaglutide is effective in reducing kidney-related complications and improving survival outcomes for patients with type 2 diabetes and CKD. [4]

Semaglutide Protects Liver in T2D with NAFLD

A 2025 study concluded that semaglutide provides significant liver benefits in patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD). Compared with other antidiabetic medications, including SGLT2 inhibitors, DPP-4 inhibitors, and thiazolidinediones, semaglutide was associated with a lower risk of major adverse liver outcomes (MALO), such as decompensated cirrhosis, liver cancer, and liver transplantation.

In addition to protecting the liver, semaglutide also reduced all-cause mortality compared with the other drug classes. These results suggest that semaglutide not only improves glycaemic control but also offers direct benefits for liver health, making it a particularly effective treatment option for patients with T2D complicated by NAFLD. [5]